（文章来源：每日经济新闻） 每经AI快讯，12月19日，创新药概念震荡反弹，益方生物涨超10%，新诺威、维康药业、亚虹医药、阳 光诺和、悦康药业跟涨。 ...

海思科今年以来股价涨59.34%，近5个交易日跌3.93%，近20日跌6.48%，近60日跌4.02%。 12月19日，海思科盘中上涨2.04%，截至09:54，报52.55元/股，成交1620.64万元，换手率0.06%，总市 值588.52亿元。 资金流向方面，主力资金净流出43.16万元，大单买入150.72万元，占比9.30%，卖出193.89万元，占比 11.96%。 截至9月30日，海思科股东户数1.29万，较上期增加12.87%；人均流通股37342股，较上期减少11.40%。 2025年1月-9月，海思科实现营业收入33.00亿元，同比增长19.95%；归母净利润2.95亿元，同比减少 22.66%。 分红方面，海思科A股上市后累计派现36.73亿元。近三年，累计派现6.87亿元。 机构持仓方面，截止2025年9月30日，海思科十大流通股东中，中欧医疗健康混合A（003095）位居第 五大流通股东，持股2139.75万股，相比上期增加12.12万股。香港中央结算有限公司位居第六大流通股 东，持股1806.01万股，相比上期增加988.04万股。工银前沿医疗股票A（001717）位居第七大流通股 ...

12月19日，指数窄幅震荡。截至9:40，上证指数涨0.04%，深证成指涨0.38%，创业板指涨0.58%。 盘面上，可控核聚变走强，王子新材、雪人集团涨停，常辅股份涨幅靠前;商业航天概念反复走强，华 体科技2连板，信科移动、广联航空等跟涨。下跌方面，贵金属、影视院线等板块跌幅靠前。 展望后市，兴业证券认为，近期重磅会议奠定的国内外积极的政策组合，创造了有利于风险资产演绎的 良好环境，跨年行情有望在寻找共识的过程中逐步展开。 热门板块 1、可控核聚变走强 2、国泰海通：跨年攻势已经开始，看好科技、券商保险、消费 国泰海通认为，政策预期有望上修，市场交投有望活跃，在较长时间的横盘震荡后，中国"转型牛"将重 振旗鼓，拾级而上并站上新高度。跨年攻势已经开始，看好科技/券商保险/消费。春季行情风格特征为 大盘搭台，小盘唱戏，以春节附近为分水岭。在此之前受年报预告压力、险资配置偏好等影响，以中证 800为代表的大盘风格占优;春节后步入经济与业绩空窗期，叠加流动性环境季节性改善，以中证2000为 代表的中小成长显著跑赢。 3、中信建投：牛市底层逻辑仍在，跨年有望迎来新一波行情 中信建投证券指出，从9月初至12月初，AH两 ...

中信建投（601066）证券研究所12月19日发表最新研报表示：港股迎来年内最后一次交易窗口。 恒生互联网ETF（513330.SH）聚焦互联网巨头（腾讯控股、阿里巴巴、美团、小米、百度等），也是 持有人户数最多的港股类ETF； 在经历了9月的单边上涨后，10月以来港股市场随着海外宏观预期反复的影响经历了震荡调整。随着AH 两地同步完成中期调整，当前港股部分优质资产重新进入高性价比区间，在北水持续配置、盈利预期修 复及年末宏观预期改善的共振下，港股正迎来一个不容忽视的年内交易窗口。 港股通科技ETF基金（159101.SZ）覆盖最广泛的港股科技细分行业，包含AI应用、创新药、机器人、 智能车等热门概念。 港股成长风格相关ETF： 恒生科技指数ETF（513180.SH）跟踪恒生科技指数规模最大的ETF； 从大周期来看，目前港股处于牛市中段。前期因风格切换而深度调整的成长板块，或伴随市场情绪回暖 与宏观不确定性消退，将凭借高盈利弹性成为引领市场的核心主线。 多重因素促成港股中期交易窗口打开：1）港股本轮经历的市场调整增厚了安全边际，为新一轮反弹预 留了足够的空间；2）南向资金依然保持净流入态势，或随着海外流动性 ...

Core Viewpoint - The Xi'an Municipal Government has released the "Implementation Plan for Promoting the Capacity Enhancement of the Biopharmaceutical Industry (2025-2027)", aiming to advance drug research and development in key areas such as stem cell drugs and peptide drugs, while also enhancing the competitiveness of enterprises in the innovative drug sector [1][2]. Industry Development Goals - By 2027, the biopharmaceutical industry in Xi'an is expected to reach a scale of 40 billion yuan, with specific targets for traditional Chinese medicine, chemical drugs, biological drugs, medical devices, and consumer healthcare [1]. - The plan aims for the approval of 1 clinical drug and 1 production drug in the innovative drug sector, as well as 40 Class III medical devices and 400 Class II medical devices by 2027 [2]. Innovation and Collaboration - The plan emphasizes breakthroughs in core technologies for drug development, particularly in stem cell and peptide drugs, and encourages collaboration between pharmaceutical companies and academic institutions for research and development [2][3]. - A full-chain collaborative system covering research, clinical trials, approval, manufacturing, and market access is to be established to facilitate innovation in the pharmaceutical industry [2]. Focus on Cell Therapy - The plan includes a specific initiative for the industrialization of cell therapy technologies, focusing on stem cell therapy, immune cell therapy, and cell-derived therapies [3][4]. - It supports partnerships with universities and medical institutions to advance clinical research in areas such as gastric and liver cancer [3]. Policy Support Across Regions - Multiple cities, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies to support the innovative drug industry, indicating a new cycle of policy support for the pharmaceutical sector [4][5]. - Specific measures include reducing clinical trial approval times and providing financial support for innovative drug development [5]. Market Outlook - Analysts note that the pharmaceutical industry is experiencing a new cycle of policy support, with a focus on "hard innovation" assets and those with strong international potential [6]. - The Chinese innovative drug sector is positioned to maintain competitive advantages in emerging technologies and disease targets, with a focus on "innovation + internationalization" as a core strategy moving forward [6].

深耕创面愈合领域的华芢生物，PDGF（血小板衍生生长因子）药物核心技术持续突破，核心产品Pro-101-2候选药临床进程顺利推进。同时公司港股上市进 入新阶段，开启技术产业化与市场扩张的双重征程。 值得一提的是，华芢生物的创新实践兼具产业价值与社会担当。Pro-101-2通过缩短愈合周期、减少重复诊疗，降低患者治疗成本，同时缓解医疗资源消耗 与医保支出压力，形成"患者-家庭-医疗体系"三方共赢格局。随着上市进程的稳步推进，华芢生物将获得更充足的资金支持，持续推进核心产品研发与管线 拓展，其在PDGF领域的技术积累与产业实践，也将为中国创新药行业的高质量发展提供务实参考。 作为破解糖尿病足溃疡难愈合痛点的关键药物，华芢生物自主研发的Pro-101-2候选药展现出突出技术优势。PDGF的临床价值已获国际公认，其通过刺激细 胞增殖、促进血管再生的作用机制，能针对性解决糖足治疗难题。华芢生物攻克技术瓶颈后，使该候选药活性较全球同类获批药物提升75倍，在安全性与有 效性上构建核心竞争力。目前Pro-101-2已稳步推进Ⅱ期临床，预计2027年第二季度完成该阶段研究，有望成为国内首款针对糖足的PDGF治疗药物。 在研发布 ...

西藏药业当前最新价为41.03元，今年以来，西藏药业股价累计上涨16.28%。此次公告拟定的最高回购 价格，比现价高34.05%。 12月18日，西藏药业公告，公司拟以集中竞价交易方式回购股份。回购金额不低于1.7亿元且不超过2亿 元；回购价格不超55.00元/股。资金来源为自有资金，回购期限为12个月内。 截至9月30日，西藏药业股东户数4.54万，较上期增加0.57%；人均流通股7092股，较上期减少0.57%。 2025年1月-9月，西藏药业实现营业收入20.89亿元，同比减少3.96%；归母净利润7.22亿元，同比减少 8.85%。 分红方面，西藏药业A股上市后累计派现22.58亿元。近三年，累计派现15.80亿元。 机构持仓方面，截止2025年9月30日，西藏药业十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股365.85万股，相比上期增加106.82万股。创新药（159992）位居第九大流通股东，持股 158.17万股，为新进股东。南方中证1000ETF（512100）位居第十大流通股东，持股147.59万股，为新 进股东。华夏行业景气混合A（003567）退出十大流通股东之列。 风 ...

Market Overview - The indices experienced fluctuations, with the ChiNext index dropping over 2% in the afternoon session [1] - The Shanghai Composite Index closed at 3876.37 points, up 0.16%, while the Shenzhen Component Index closed at 13053.97 points, down 1.29%, and the ChiNext Index at 3107.06 points, down 2.17% [2][14] Sector Performance - The pharmaceutical retail sector showed strong performance, with stocks like Shangyu Pingmin and Huaren Health hitting the daily limit [1] - The retail sector was active, with companies such as Central Plaza and Yimin Group also reaching the daily limit [1] - The banking sector rebounded in the afternoon, with Shanghai Bank leading the gains [1] - Conversely, the Hainan sector saw significant declines, particularly Haima Automobile, while the battery sector continued to fall, led by Huasheng Lithium [1][15] Hot Sectors - **Pharmaceutical Retail**: The AI health app "Ant Financial Health" saw a surge in downloads, reaching third place on the Apple app store, with over 15 million monthly active users [4][16] - **Storage Chips**: Micron Technology reported better-than-expected earnings for Q1 FY2026, raising its capital expenditure forecast from $18 billion to $20 billion due to tight supply and rising prices in the storage chip market [5][17] Monetary Policy - The People's Bank of China conducted a 883 billion yuan reverse repurchase operation with a 1.40% interest rate, alongside a 1000 billion yuan 14-day reverse repurchase operation to stabilize liquidity [19] - There are expectations for a potential reserve requirement ratio (RRR) cut in early 2026, estimated at 0.5 percentage points, injecting approximately 1 trillion yuan into the market [19] Industry Insights - The China Photovoltaic Industry Association reported a price recovery in the photovoltaic sector, with average prices for polysilicon increasing by 34.4% year-on-year as of November [20] - The investment outlook for 2026 suggests a focus on sectors like AI, new energy, military, and innovative pharmaceuticals, with a shift towards cash flow generation in stock selection [21]

Group 1 - The core viewpoint of the news highlights the performance of the ChiNext ETF Tianhong (159977), which has seen significant capital inflow despite a decline in the ChiNext Index (399006) by 1.78% [1][2] - As of December 18, 2025, the trading volume of the ChiNext ETF Tianhong reached 161 million yuan, with a notable subscription of 40 million shares [1][2] - The ETF has experienced a growth of 1.26 billion yuan in the past week and an increase of 10.62 billion shares over the last six months, indicating strong demand [2] Group 2 - The ChiNext ETF Tianhong tracks a diverse index that includes high-growth sectors such as pharmaceuticals, new energy, computing power, and brokerage, which are expected to benefit from trends like innovation in pharmaceuticals and strong demand for AI computing power [2] - The current Price-to-Earnings (PE) ratio of the index is 40.51, which is in the relatively undervalued zone at the 33.79% historical percentile since its inception, suggesting attractive investment value [2] - The launch of humanoid robots in CATL's battery production line marks a significant milestone in the application of embodied intelligence in smart manufacturing [4] Group 3 - Institutional views suggest that the market is currently in a high-level consolidation phase, with expectations for a structural bull market in 2026, favoring cyclical and value styles in the first half of the year [4][5] - The economic environment for 2026 is expected to be more balanced and stable, supporting a positive trend in the equity market [5]

Core Viewpoint - The stock of Shenzhen Sinopharm Holdings Co., Ltd. (信立泰) has experienced fluctuations, with a year-to-date increase of 82.55% but a recent decline in the last five and twenty trading days [1][2]. Group 1: Stock Performance - As of December 18, the stock price was 55.55 CNY per share, with a market capitalization of 619.28 billion CNY [1]. - The stock has seen a net outflow of 572.07 thousand CNY in principal funds, with significant selling pressure in large orders [1]. - Year-to-date, the stock has risen by 82.55%, but it has decreased by 6.15% in the last five trading days and 9.04% in the last twenty trading days [1]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 32.41 billion CNY, representing a year-on-year growth of 8.00%, and a net profit attributable to shareholders of 5.81 billion CNY, up 13.93% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 72.04 billion CNY, with 16.49 billion CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 25,200, with an average of 44,249 circulating shares per person, a decrease of 4.64% from the previous period [2]. - The top circulating shareholders include notable funds, with 中欧医疗健康混合A (003095) being the second-largest shareholder, increasing its holdings by 1.0162 million shares [3].